×

·BAG3 contributes to HGF-mediated cell proliferation, migration, and invasion via the Egr1 pathway in gastric cancer. Tumori Journal, 2019
( 위암 전이에서 BAG3 유전자의 역할)

·Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer. Cancer Res Treat, 2019
(위암 환자에게 1차 항암제 사용시 치료 방법과 변경)

·Microsatellite Instability and Programmed Cell Death-Ligand 1 in Stage II/III Gastric Cancer Post Hoc Analysis of the CLASSIC Randomized Controlled study. Ann Surg, 2018
(위암에서 유전자의 발현)

·Phase II Study of Divitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05).Cancer Res Treat, 2018
(전립선암에서 Divitinib 표적 치료제의 효과)

·Phase II study of oxaliplatin, irinotecan and S?1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14?11. Gastric Cancer, 2018
(진행성 위암에서 3제요법의 항암효과)

·S-1 d Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial. Cancer Res Treat, 2018
(위암수술후 보조치료로서 S-1 근간 항암치료 효과)

·Experiences and Opinions Related to End-of-Life Discussion: From Oncologists' and Resident Physicians' Perspectives. Cancer Res Treat, 2018
(임종기 환자에서 암 전문가의 경험과 의견)

·Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naive Korean Patients with Extensive-Disease Small Cell Lung Cancer. Cancer Res Treat, 2018
(확장기 소세포폐암에서 EP와 IP 항암제의 효과비교)

·HGF-mediated S100A11 over enhances proliferation and invasion of gastric cancer. Am J Transl Res, 2018
(위암세포주에서 S100유전자의 역할)

·Predictive test for chemotheraphy response in resectable gastric cancer: a multi-cohort, retrospective analysis. Lancet Oncol, 2018
(수술한 위암에서 항암치료 반응 예측 )

·Antiemetic Corticosteroid Rotation from Dexamethasone to Methylprednisolone to Prevent Dexamethasone-Induced Hiccup in Cancer Patients Treated with Chemotherapy: A Randomized, Single-Blind, Crossover Phase lllTrial. The Onclogist, 2017
(항암치료시 항구토제의 역할)

·Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial. Chinese Journal of Cancer, 2017
(암성 통증 치료시 저니스타의 효과 와 안정성)

·Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non?Small-Cell Lung Cancer. J Clin Oncol. 2017
(비소세포폐암에서 Motesanib (AMG-706) 약제의 효과)


·Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach. British Journal of Cancer, 2017
(위장관 연부 육종암에서 선행항암치료의 효과)

·Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol, 2017
(전신상태가 불량한 비소세포 폐암 환자에서 2제 항암제의 비교)

·Multicenter Phase II Clinical Trial of Genexol-PM® with Gemcitabine in Advanced Biliary Tract Cancer. Anticancer Research 2017
(진행성 담도암에서 2제 항암치료의 효과)

·Triplet cytotoxic chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced pancreatic cancer. Oncology Letter, 2015
(진행성 췌장암에서 3제 항암제의 효과)

·A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with static Colorectal Cancer: J of Cancer, 2015
(전이성 대장암에서 2제 항암제의 비교)

·HGF mediated upregulation of lipocalin 2 regulates MMP9 through nuclear factor-kappa B activation. Oncol report, 2015
(위암 세포주에서 lipocalin-2의 암전이 에서 역할)

·Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or static esophageal squamous cell carcinoma. Oncotarget, 2015
(전이성 식도암에서 dacomitinib 표적 치료의 역할)

·Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non?Small-Cell Lung Cancer: KCSG-LU05-04. J of Clin Oncol, 2015
(비소세폐암에서 항암방사선치료와 치료후 추가 항암치료의 효과 비교)

·Multicenter phase Ⅱ study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. European J of Cancer, 2015
(진행성 위암에서 3제 항암치료효과)

·Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. Gastirc Cancer, 2015
(진행성 위암환자에서 nimotuzumab을 추가한 2제 요법의 효과)

·Phase I/II study of Weekly Oraxol for the second-line treatment of patiebts with static or recurrent gastric cancer. The Oncologist, 2015
(진행성 위암에서 경구용 오락솔의 효과)

·Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy(CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet, 2012
(수술후 재발 방지 위한 항암치료의 효과)